Skip to main content
    N

    Neuroone Medical Technologies Corp (NMTC)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $0.74
    -0.00 (-0.01%)

    Market Cap: $6.78M

    Last updated: Nov 17, 2026 at 11:00 AM ET

    Neuroone Medical Technologies Corp (NMTC) Financials: Revenue, Profit and Cash Flow

    Updated Aug 13, 2026. Financial statements from company filings, amounts in US dollars.

    Neuroone Medical Technologies reported revenue of $12.10M for the fiscal year ended Sep 30, 2025, up 250.4% from the year before. That year, net income was -$3.61M with a net margin of -29.8%, operating cash flow was -$2.84M and free cash flow was -$2.92M. The quarter ended Jun 30, 2026 had revenue of $1.97M and net income of -$2.01M.

    Revenue and Margins

    The operating margin was -34.9% in the fiscal year ended Sep 2025. Over the 9 years to Sep 2025, revenue grew from $742, a compound annual rate of 193.8%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Sep 2025$12.10M+250.4%67.3%-34.9%-29.8%
    Sep 2024$3.45M+76.9%31.3%-344.3%-356.7%
    Sep 2023$1.95M+1040.7%23.4%-612.3%-607.4%
    Sep 2022$171.17K-3.9%-41.4%-5860.2%-5842.0%
    Sep 2021$178.15K-90.8%-54.9%-5735.9%-5584.3%
    Sep 2020$1.93MN/A96.3%-254.5%-708.0%
    Sep 2019$0N/AN/AN/AN/A
    Sep 2018$0N/AN/AN/AN/A
    Sep 2017$0-100.0%N/AN/AN/A
    Sep 2016$742N/A100.0%-4166.4%-8472.1%
    Annual, fiscal years ended Sep 2016 to Sep 2025

    Income Statement

    In the fiscal year ended Sep 2025, the net loss narrowed from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018Sep 2017Sep 2016
    Revenue$12.10M$3.45M$1.95M$171.17K$178.15K$1.93M$0$0$0$742
    Cost of revenue$3.96M$2.37M$1.50M$241.96K$275.89K$70.55K$27.57K$21.67K$7.74K$0
    Gross profit$8.14M$1.08M$456.52K-$70.79K-$97.75K$1.86M-$27.57K-$21.67K-$7.74K$742
    Research and development$4.98M$5.07M$6.94M$4.93M$3.93M$2.08M$1.53M$951.06K$735.33K$735.33K
    Operating income-$4.23M-$11.89M-$11.96M-$10.03M-$10.22M-$4.90M-$5.81M-$3.21M-$32.61K-$30.91K
    Net income-$3.61M-$12.32M-$11.86M-$10.00M-$9.95M-$13.64M-$6.78M-$6.83M-$47.77K-$62.86K
    EBITDA-$3.01M-$11.84M-$11.66M-$9.88M-$9.86M-$4.85M-$5.79MN/A-$14.98K-$30.91K
    Fiscal years ended Sep 2016 to Sep 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$1.97M$2.39M$2.89M$2.74M$1.70M$1.39M$3.27M$272.28K$825.78K$1.38M$977.65K$741.78K
    Gross profit$1.18M$1.29M$1.57M$1.53M$914.84K$771.06K$1.93M$141.06K$281.87K$390.42K$266.31K$193.66K
    Operating income-$2.42M-$2.10M-$1.71M-$1.37M-$1.89M-$2.68M$1.71M-$2.82M-$2.79M-$2.89M-$3.39M-$3.16M
    Net income-$2.01M-$2.09M-$1.44M-$1.62M-$1.50M-$2.27M$1.79M-$3.35M-$2.77M-$2.86M-$3.34M-$3.14M
    Last 12 quarters

    Balance Sheet

    As of Sep 2025, cash and equivalents exceeded short-term debt of $123.66K by $6.45M.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018Sep 2017Sep 2016
    Total assets$10.79M$5.37M$8.10M$12.82M$7.94M$4.76M$532.62K$218.72K$756.93K$1.84K
    Current assets$10.23M$4.63M$7.31M$12.18M$7.29M$4.16M$301.75K$18.64K$576.04K$1.84K
    Cash and equivalents$6.57M$1.46M$5.32M$8.16M$6.90M$4.04M$260.75K$13.26K$522.22K-$1.84K
    Total liabilities$3.71M$4.55M$1.85M$3.22M$1.38M$2.69M$1.77M$4.61M$1.02M$83.33K
    Short-term debt$123.66K$65.77K$129.12K$83.34K$112.78K$1.07MN/A$1.68M$275.20K$13.62K
    Shareholder equity$7.07M$822.01K$6.25M$9.60M$6.55M$2.07M-$1.24M-$4.40M-$266.22K-$81.49K
    Fiscal years ended Sep 2016 to Sep 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$6.19M$7.86M$8.58M$10.79M$10.82M$4.46M$6.49M$5.37M$4.91M$5.39M$5.82M$8.10M
    Total liabilities$2.42M$2.49M$2.18M$3.71M$2.64M$3.33M$3.56M$4.55M$1.90M$1.54M$1.40M$1.85M
    Cash and equivalents$2.05M$2.80M$3.56M$6.57M$8.04M$1.32M$1.13M$1.46M$1.62M$2.43M$2.68M$5.32M
    Shareholder equity$3.77M$5.37M$6.40M$7.07M$8.18M$1.13M$2.94M$822.01K$3.01M$3.85M$4.42M$6.25M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Sep 2025.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018Sep 2017Sep 2016
    Operating cash flow-$2.84M-$11.01M-$12.89M-$7.52M-$8.60M-$3.43M-$5.40M-$2.83M-$21.11K-$30.23K
    Capital expenditures$81.74K$120.20K$384.12K$275.23K$67.08K$122.43K$123.35K$91.71K$91.71K$58.35K
    Free cash flow-$2.92M-$11.13M-$13.27M-$7.79M-$8.67M-$3.55M-$5.52M-$2.92M-$112.81K-$88.58K
    Investing cash flow-$81.74K-$120.20K$2.65M-$3.24M-$67.08K-$122.43K-$123.35K-$146.71K-$91.71K-$91.71K
    Financing cash flow$8.03M$7.27M$7.40M$12.02M$11.53M$7.32M$5.77M$2.92M$21.11K$30.02K
    Fiscal years ended Sep 2016 to Sep 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$1.08M-$1.33M-$3.12M-$1.53M-$1.46M-$56.14K$208.05K-$2.67M-$2.36M-$2.18M-$3.81M-$2.90M
    Capital expenditures$19.66K$38.52K$40.75K$10.61K$43.55K$3.17K$24.42K$36.91K$14.80K$31.36K$37.13K$57.62K
    Free cash flow-$1.10M-$1.37M-$3.16M-$1.54M-$1.51M-$59.31K$183.63K-$2.70M-$2.38M-$2.21M-$3.85M-$2.96M
    Last 12 quarters

    Frequently Asked Questions About NMTC

    What is Neuroone Medical Technologies' annual revenue?

    Neuroone Medical Technologies reported revenue of $12.10M for the fiscal year ended Sep 30, 2025.

    How fast is Neuroone Medical Technologies' revenue growing?

    Revenue was up 250.4% for the fiscal year ended Sep 30, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 313.5%.

    Is Neuroone Medical Technologies profitable?

    No. Neuroone Medical Technologies reported net income of -$3.61M for the fiscal year ended Sep 30, 2025, with a net margin of -29.8%.

    How much free cash flow does NMTC generate?

    For the fiscal year ended Sep 30, 2025, operating cash flow of -$2.84M minus capital expenditures of $81.74K produced free cash flow of -$2.92M.

    How much debt does Neuroone Medical Technologies have?

    The balance sheet dated Sep 30, 2025 reported short-term debt of $123.66K and cash and equivalents of $6.57M.